SILVER SPRING, Maryland (Reuters) – U.S. advisers rejected a new type of diabetes pill from AstraZeneca and Bristol-Myers Squibb over concerns about liver and cancer risks.
A Food and Drug Administration advisory panel voted 9-6 on Tuesday against recommending approval of the drug, called dapagliflozin, for adults with Type 2 diabetes.
Panel members said the clinical data did not provide enough certainty about the drug's cancer, liver and kidney risks, as well as its efficacy -- especially for the elderly.
The FDA usually follows the recommendations of its advisory panels and is due to make a final decision on the drug by October 28.
Tuesday, July 19, 2011
FDA Advisory Panel rejects AstraZeneca, Bristol diabetes pill - Yahoo! News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment